Cleared Traditional

K182123 - ATTEST Drug Screen Cup

K182123 is an FDA 510(k) clearance for ATTEST Drug Screen Cup, manufactured by Advin Biotech, Inc.. The device is a Class 2 Toxicology device with product code DJG cleared through the Traditional 510(k) pathway after a 235-day FDA review.

K182123 · Advin Biotech, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2019
Decision
235d
Days
Class 2
Risk

K182123 is an FDA 510(k) clearance for the ATTEST Drug Screen Cup, ATTEST Drug Screen Dip Card. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Advin Biotech, Inc. (San Diego, US). The FDA issued a Cleared decision on March 29, 2019 after a review of 235 days - an extended review cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3650 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Advin Biotech, Inc. devices

FDA 510(k) Submission Details - K182123

510(k) Number K182123 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 06, 2018
Decision Date March 29, 2019
Days to Decision 235 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
148d slower than avg
Panel avg: 87d · This submission: 235d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DJG Device Classification - Class 2, Special Controls

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 149
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K182123.
ARK Fentanyl II Assay
K200197 · ARK Diagnostics, Inc. · Feb 2020
CEDIA Heroin Metabolite (6-AM) assay
K192943 · Microgenics Corporation · Dec 2019
Psychemedics Microplate EIA for Fentanyl in Hair
K182103 · Psychemedics Corporation · Apr 2019
ARK Tramadol Assay
K182280 · ARK Diagnostics, Inc. · Dec 2018
LZI Fentanyl Enzyme Immunoassay
K181159 · Lin-Zhi International, Inc. · Dec 2018
ARK Fentanyl Assay
K180427 · ARK Diagnostics, Inc. · Jun 2018